标题
PEG10 is associated with treatment-induced neuroendocrine prostate cancer
作者
关键词
-
出版物
JOURNAL OF MOLECULAR ENDOCRINOLOGY
Volume 63, Issue 1, Pages 39-49
出版商
Bioscientifica
发表日期
2019-04-23
DOI
10.1530/jme-18-0226
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Clinical and molecular features of treatment-related neuroendocrine prostate cancer
- (2018) Shusuke Akamatsu et al. INTERNATIONAL JOURNAL OF UROLOGY
- Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study
- (2018) Rahul Aggarwal et al. JOURNAL OF CLINICAL ONCOLOGY
- PEG10 overexpression induced by E2F-1 promotes cell proliferation, migration, and invasion in pancreatic cancer
- (2017) Yun-Peng Peng et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer
- (2016) Etienne Dardenne et al. CANCER CELL
- PEG10 promotes human breast cancer cell proliferation, migration and invasion
- (2016) XINRAN LI et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer
- (2016) Himisha Beltran et al. NATURE MEDICINE
- The Master Neural Transcription Factor BRN2 Is an Androgen Receptor–Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer
- (2016) Jennifer L. Bishop et al. Cancer Discovery
- SRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate Cancer
- (2015) X. Zhang et al. CLINICAL CANCER RESEARCH
- Regulation of tumor cell plasticity by the androgen receptor in prostate cancer
- (2015) J. L. Bishop et al. ENDOCRINE-RELATED CANCER
- The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer
- (2015) Shusuke Akamatsu et al. Cell Reports
- Aggressive Variants of Castration-Resistant Prostate Cancer
- (2014) H. Beltran et al. CLINICAL CANCER RESEARCH
- Rb Loss Is Characteristic of Prostatic Small Cell Neuroendocrine Carcinoma
- (2013) H.-L. Tan et al. CLINICAL CANCER RESEARCH
- Next-generation Sequencing of Advanced Prostate Cancer Treated with Androgen-deprivation Therapy
- (2013) Prabhakar Rajan et al. EUROPEAN UROLOGY
- A Novel Antiandrogen, Compound 30, Suppresses Castration-Resistant and MDV3100-Resistant Prostate Cancer Growth In Vitro and In Vivo
- (2013) H. Kuruma et al. MOLECULAR CANCER THERAPEUTICS
- An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide)
- (2013) M. Korpal et al. Cancer Discovery
- A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509
- (2013) J. D. Joseph et al. Cancer Discovery
- Overcoming mutation-based resistance to antiandrogens with rational drug design
- (2013) Minna D Balbas et al. eLife
- Specific changes in the expression of imprinted genes in prostate cancer—implications for cancer progression and epigenetic regulation
- (2012) Teodora Ribarska et al. ASIAN JOURNAL OF ANDROLOGY
- Androgen Receptor Splice Variants Mediate Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cell Lines
- (2012) Y. Li et al. CANCER RESEARCH
- The mutational landscape of lethal castration-resistant prostate cancer
- (2012) Catherine S. Grasso et al. NATURE
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Modeling a Lethal Prostate Cancer Variant with Small-Cell Carcinoma Features
- (2011) V. Tzelepi et al. CLINICAL CANCER RESEARCH
- Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets
- (2011) H. Beltran et al. Cancer Discovery
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started